SynAct Pharma AB Stock

SYNACT

SE0008241491

Pharmaceuticals

Market Closed - Nasdaq Stockholm 20:00:00 15/09/2026 +04			5-day change	1st Jan Change
18.30 ^SEK	-1.72%		-6.92%	-19.03%

09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW

Last Transcript: SynAct Pharma AB

SynAct Pharma AB - Special Call

06-15

More transcripts

Analysts' recommendations: SynAct Pharma AB

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/10/25	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW

More recommendations

Press Releases: SynAct Pharma AB

09-10	SynAct Pharma to Present at Investing in Life Science on September 22	AQ
09-08	SynAct Pharma : Bolagspresentation September 2026	PU
09-08	SynAct Pharma : Company presentation	PU
09-07	SynAct on phase III plans following new ADVANCE data	AQ
09-07	SynAct Pharma : Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development – FDA discussions on trial design planned for Q4 2026	PU

More press releases

Managers and Directors: SynAct Pharma AB

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	01/01/2014
Ann Kristin Led DFI	Director of Finance/CFO	-	01/03/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	15/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	20/03/2024
Anders Kronborg CHM	Chairman	62	20/03/2024
Sten Scheibye BRD	Director/Board Member	74	20/03/2024

More insiders

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

11-02 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
15/09/26	SEK 18.30	-1.72%	33,702
14/09/26	SEK 18.62	-1.79%	61,725
11/09/26	SEK 18.96	-0.42%	105,457
10/09/26	SEK 19.04	-0.73%	96,715
09/09/26	SEK 19.18	-2.44%	123,379

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	1.02B 105M 90.81M 85.87M 77.74M 146M 10.06B 147M 394M 5.1B 394M 385M 16.26B	P/E 2026 *	-10.9x	P/E 2027 *	-18.7x
Enterprise Value	1.05B 107M 93.01M 87.95M 79.63M 149M 10.3B 151M 404M 5.22B 403M 394M 16.66B	EV / Sales 2026 *	23.7x	EV / Sales 2027 *	50.9x
Free-Float	68.66%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SYNACT	Delayed
CBOE		Real-time
Deutsche Boerse AG	8F8	Delayed
Börse Stuttgart	8F8	Delayed
CBOE		Real-time
Tradegate	8F8	Real-time
Boerse Muenchen	8F8	Real-time

09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW
09-07	Synact Pharma sees support for phase 3 after post hoc analysis	FW
09-07	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon	CI
09-03	Stockholm stocks rise, Clas Ohlson jumps on earnings, OMXS30 index up 0.6 percent	FW
09-03	Synact Pharma CEO and head of research sell shares for tax reasons	FW
08-28	Synact Pharma to present new preclinical data for resomelagon at WCI	FW
08-28	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026	CI
08-20	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Synact Pharma reports narrower operating loss	FW
08-20	Calendar Thursday, August 20	FW
08-19	Synact Pharma signs term sheet with Hipolabor on resomelagon in Brazil	FW
08-19	SynAct Pharma AB and Hipolabor Farmacêutica LTDA Sign Term Sheet for Co-Development and Commercialization Partnership for Treatment of Dengue In Brazil	CI

1 day	-1.72%
1 week	-6.92%
Current month	-8.50%
1 month	-8.22%
3 months	+51.24%
6 months	+4.45%
Current year	-19.03%

1 week	18.2	19.44
1 month	16.84	22.45
Current year	7.05	24.4
1 year	7.05	25.3
3 years	4.98	25.3
5 years	4.98	146
10 years	4.8	146

SynAct Pharma AB Stock

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news: SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/09/26	Jeppe Øvlesen	Sell	Founder	-150,000	0.2813%
02/09/26	Thomas Jonassen	Sell	Chief Technology Officer	-350,000	0.6563%
10/03/26	Anders Kronborg	Buy	Chairman	2,750	0.0052%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	-1.72%	-6.92%	+0.22%	+6.89%	107M
ELI LILLY AND COMPANY	-0.19%	+1.09%	+51.85%	+97.36%	1,015B
JOHNSON & JOHNSON	+0.33%	-0.71%	+50.62%	+65.50%	642B
ABBVIE INC.	+0.49%	+5.73%	+20.88%	+72.92%	463B
ROCHE HOLDING AG	-0.22%	+2.88%	+38.48%	+37.98%	353B
NOVARTIS AG	-0.07%	+1.82%	+16.57%	+23.39%	265B
ASTRAZENECA PLC	-0.31%	+2.02%	+6.15%	+10.75%	254B
AMGEN INC.	-1.53%	-4.46%	+36.90%	+44.08%	206B
NOVO NORDISK A/S	-1.60%	-5.51%	-22.30%	-58.60%	191B
GILEAD SCIENCES, INC.	+0.49%	-0.23%	+30.00%	+93.34%	182B
Average	-0.25%	-1.31%	+22.94%	+39.36%	357.03B
Weighted average by Cap.	+0.40%	+0.00%	+34.47%	+59.29%

	2026 *	2027 *
Net sales	44.25M 4.53M 3.92M 3.71M 3.36M 6.3M 434M 6.35M 17.02M 220M 17.01M 16.63M 702M	21.6M 2.21M 1.91M 1.81M 1.64M 3.08M 212M 3.1M 8.31M 107M 8.3M 8.12M 343M
Net income	-47.08M -4.82M -4.17M -3.95M -3.57M -6.7M -462M -6.75M -18.11M -234M -18.09M -17.69M -747M	-31.92M -3.27M -2.83M -2.67M -2.42M -4.54M -313M -4.58M -12.28M -159M -12.27M -11.99M -507M
Net Debt	24.81M 2.54M 2.2M 2.08M 1.88M 3.53M 243M 3.56M 9.55M 123M 9.53M 9.32M 394M	74.22M 7.59M 6.58M 6.22M 5.63M 10.57M 728M 10.65M 28.55M 369M 28.52M 27.89M 1.18B